BioCentury | Jun 11, 2020
Deals

Cullinan adds first-in-class asset in hot NK cell checkpoint space

The latest addition to Cullinan’s oncology portfolio is a mAb against MICA that’s set to become the first compound in the clinic against the NK cell target. Through a deal announced on Thursday, Cullinan Oncology...
BioCentury | Dec 27, 2019
Company News

Two-year-old Xyphos gains exit as Astellas scoops up CAR T switch platform

After splitting from parent company AvidBiotics in 2017, Xyphos has taken a short path to reward the decision with a takeout by Astellas. The Japanese pharma will use the technology to build its immuno-oncology pipeline,...
BioCentury | Oct 16, 2019
Company News

GammaDelta spins out Adaptate to focus on antibody therapies

As GammaDelta nears bringing its T cell therapies to the clinic, it’s spinning out Adaptate to focus on the development of its γδ antibody-based programs. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) has a time-limited option...
BioCentury | Jul 19, 2019
Product Development

Why GammaDelta would do its Takeda build-to-buy all over again

Two years in, GammaDelta says the $100 million Takeda option deal it signed months after launching gave the company a boost that would have been hard to come by any other way. Build-to-buy deal structures...
BioCentury | Jun 8, 2018
Tools & Techniques

NK cell check-in

...LLC CuraB-20 Antibody MICA / MICB Preclin Innate Pharma S.A. (Euronext:IPH) IPH4301 Antibody MICA / MICB...
...programs against MICB for cancer. CanCure’s preclinical mAbs CuraB-10 and CuraB-20 target both MICA and MICB...
...domains long cytoplasmic tail 3 MICA - MHC class I polypeptide-related sequence A MICB - MHC class I polypeptide-related sequence B...
BioCentury | Apr 13, 2018
Targets & Mechanisms

Hello RNA

...cells. Among emerging targets, the single biggest increase in mentions from 2017 to 2018 is MICB...
...T cells. One abstract showed miR-183 targets MICB, and inhibition of the miRNA can prevent MICB-mediated...
...protein 1 LAPTM5 - Lysosomal protein transmembrane 5 MAPK; ERK - MAP kinase MICB - MHC class I polypeptide-related sequence B...
BioCentury | Apr 3, 2018
Distillery Therapeutics

Cancer

...Melanoma, colorectal cancer Mouse studies suggest antibodies against the conserved α3 domain of MICA and MICB...
...metastases compared with an isotype control antibody. In a second mouse model of MICA- and MICB-expressing...
...Cancer Institute, Boston, Mass. email: kai_wucherpfennig@dfci.harvard.edu Jennie Walters Dana-Farber Cancer Institute MHC class I polypeptide-related sequence A (MICA) MHC class I polypeptide-related sequence B (MICB) Colorectal...
BioCentury | Mar 30, 2018
Preclinical News

Targeting stress proteins on cells to help treat cancer

...efforts. Many cancers express the stress proteins MHC class I polypeptide-related sequence A (MICA) and MICB...
...MICA and MICB alpha 3 domains could be combined with therapies that trigger MICA and MICB...
...approved drugs, Wucherpfennig said. Jennie Walters Dana-Farber Cancer Institute Harvard Medical School MHC class I polypeptide-related sequence A (MICA) MHC class I polypeptide-related sequence B (MICB...
BioCentury | Oct 5, 2017
Product R&D

Avidly specific

With its first two programs headed for the clinic next year, AvidBiotics Corp. is seeing the fruits of its move to human therapeutics from food safety and animal health. Using engineered peptides, the company has...
BioCentury | Jun 29, 2017
Product R&D

Drop the MIC

...STAGE Product mAbs against soluble MICA and MICB Concept Blocking the activity of MICA and MICB...
...MICB. Animals treated with an anti-CTLA-4 mAb that had low levels of soluble MICA and MICB...
...of the soluble ligands. The second model used transgenic mice expressing MICB and harboring syngeneic MICB-expressing...
Items per page:
1 - 10 of 21